Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Sponsor
Regeneron Pharmaceuticals (Industry)
Overall Status
Available
CT.gov ID
NCT06132191
Collaborator
(none)
Study Details
Study Description
Brief Summary
Provide expanded access of cemiplimab in patients with solid tumors
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.
Study Design
Study Type:
Expanded Access
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Regeneron Pharmaceuticals
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT06132191
Other Study ID Numbers:
- R2810-Cemiplimab
First Posted:
Nov 15, 2023
Last Update Posted:
Nov 15, 2023
Last Verified:
Nov 1, 2023
Additional relevant MeSH terms: